Home / Investors / Overview

Company Information

CymaBay Therapeutics (Nasdaq: CBAY)

We are a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need. We are evaluating seladelpar in primary biliary cholangitis (PBC) and NonAlcoholic SteatoHepatitis (NASH). We also have two product programs in earlier development that feature unique mechanisms of action and have potential in liver and chronic diseases.

Stock Information

Last Change Volume

Shares Outstanding: 10,064,495
(as of March 3, 2014)

Company Information

CymaBay Therapeutics
7575 Gateway Blvd
Suite 110
Newark, CA 94560

Investor Relations

Sujal Shah
(510) 293-8800

Recent News


CymaBay Therapeutics Announces Departure of Chief Medical Officer


CymaBay Therapeutics to Present at Upcoming Investor Conferences in September


CymaBay Reports Second Quarter 2019 Financial Results and Provides Corporate Update

Upcoming Event

Sep 24 2019 8:00 am ET

Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Disease Companies

September 24, 2019 at 8:00 am ET

Q2 2019 Quarterly Results